Abstract
Unlike the antibiotics erythromycin and penicillin G, sodium fusidate (fusidin) pretreatment (80 mg/kg of body weight) increased the survival rate of neonatal BALB/c mice challenged with Salmonella enteritidis lipopolysaccharide. Fusidin also significantly reduced the plasma tumor necrosis factor alpha levels. Hence, fusidin may prove useful in the management of bacterial sepsis in humans.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Disease Models, Animal
-
Female
-
Fusidic Acid / pharmacology*
-
Lipopolysaccharides
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Shock, Septic / blood
-
Shock, Septic / drug therapy*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Anti-Bacterial Agents
-
Lipopolysaccharides
-
Tumor Necrosis Factor-alpha
-
Fusidic Acid